12 September 2018
Ameer Khan By Ameer Khan

Flexible Packaging If A has Bought B, What Happens to C?

Amcor’s recent announcement of their agreement to purchase Bemis for $6.8B USD is the biggest news to hit the flexible package industry in years. It marks the coming together of 2 industry giants and is set to shake up the global industry. But what will the new company look like?

The new look Amcor/ Bemis, known as New Amcor, promises to be a beast. Just look at the numbers involved. The new company will have a combined turnover of $17B USD, over 250 plants and 50,000 employees across more than 40 countries. Bemis President and CEO William Austen said the agreement will create ‘a global leader in consumer packaging’, and he’s certainly right as the move is made from competitor to collaborator.

Flexible packaging will make up an estimated $9B of the new business. New Amcor aims to be better than the sum of its parts, with better coverage of emerging markets than (Old?) Amcor and will maintain a presence in all current key Bemis locations. Bemis brings a much bigger presence in North and Latin America than Amcor currently has, additionally bringing some major clients from the food industry to the table.

What about C&D?

One company who will be paying particular attention to the news is Constantia Flexibles, or the ‘C’ to Amcor and Bemis’ A&B. Whilst the presumed disappearance of one of their competitors will bump them up the global rankings, it remains to be seen how the combined strength of New Amcor will impact their traditionally strong market position in Europe.

They recently announced their latest technological breakthrough in the pharma packaging space at Healthcare Packaging Expo, but they’ll now have a bigger fight on their hands than ever to stay ahead. Having spoken to a range of employees from Constantia, I know that they’re excited about the new challenge and up for the fight.

Another business that will be gearing up to compete with New Amcor and has undergone significant change of its own is Coveris. They sold off their Coveris Americas packaging business earlier this year for more than $1.7B to Transcontinental Inc. and also invested in their UK facility to increase their capacity, demonstrating their commitment to sustainable packaging.

Coveris look to have been trimming off non-key areas of their business and doubling down on their strengths – presumably to leave them as a leaner, more efficient competitor in their key markets.

Looking Forward

It remains to be seen what will happen for employees of New Amcor as no merger is ever 100% complimentary. The impact will hopefully be a positive one for the wider industry, although we’ll have to wait and see exactly what will happen.

Share
Back to the top
Ameer Khan

Ameer Khan has been with CM Life Science since 2017. Today he is a Principal Consultant working within the Pharma Services, Packaging and Drug Delivery spaces. Ameer oversees key accounts for the company, while also looking to expand his customer base and build lasting relationships. He has experience recruiting commercial and technical candidate's all over the world and is truly a specialist within his markets.

Recommended.

Innovative Drug Delivery Systems Taking the Market By Storm.
09 September 2022
Ameer Khan By Ameer Khan

Innovative Drug Delivery Systems Taking the Market By Storm.

In a space of increased innovation in drug delivery, I took a deeper look into the leading products taking the market by storm.

Building an Impactful Talent Strategy for Your Life Science Start-Up
16 August 2022
Eleanor Doolin Nathan Sharpe By Eleanor Doolin & Nathan Sharpe

Building an Impactful Talent Strategy for Your Life Science Start-Up

Are you attracting the very best industry talent to your start-up? For expert advice on how to thrive in today’s life science talent market, watch CM Life Science's latest 30-minute webinar. Click to watch.

The Impact of COVID-19 on Clinical Trial Supply.
08 December 2021
Ameer Khan By Ameer Khan

The Impact of COVID-19 on Clinical Trial Supply.

We talk to Tim Roberts, who’s Chief Commercial Officer at PCI Pharma Services. Click to listen to his experiences in and predictions for the clinical trial supply market.

"Always be Visible and Always be Available"
08 July 2021
Joe Bakali By Joe Bakali

"Always be Visible and Always be Available"

In this episode of CM Conversations, our guest share his tips on hitting the ground running and building a team remotely, as well as the importance of investing in relationships. In his words, you should always be visible and available.